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IntRoductIon
Severe acute respiratory syndrome (SARS) COV-2), the seventh 
coronavirus in history, is the causative agent of COVID-19 
disease. This virus, which is now known to cause SARS took its 
origin from the People’s Republic of China in December 2019.[1] 
Within a few months of onset, COVID-19 spread so fast and 
crossed several international borders, which led to the WHO 
declaring it a pandemic on March 11, 2020.[2] Despite lockdowns 
and restrictions in various forms of movement imposed 
in different countries, the disease is still rapidly spreading 
worldwide, probably due to lack of protective equipment[3] 
or due to the culture of doubts that exist in the minds of some 
individuals, especially among Africans who question the reality 
of the existence of the disease. Failure of some countries to act 
fast during the earlier phase of the COVID-19 has equally been 
attributed to the recent spike in these countries[4] as well as 
poor compliance with safety measures or guidelines. Intestinal, 
respiratory, neuronal, and hepatic diseases have all been 
linked to various forms of coronaviruses and SARS-CoV-2, 
as well as organ failure and even death in severe cases.[5,6] A 
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recent study has equally reported an association between the 
severity of COVID-19 and some analytes such as Vitamin 
D.[7] In addition, COVID-19 infection has been associated 
with abnormally elevated levels of inflammatory markers, 
which could explain why infected patients are at greater risk 
for more severe disease and death, especially in the presence 
of comorbidities such as diabetes, cancer, and hypertension.[8] 
More severe disease in COVID-19 patients may also be as a 
result of a cytokine storm.[8] Although the non specific use of 
inflammatory markers in diagnosing serious underlying disease 
has been reported, their measurement can either give a marker 
of treatment response or be used to detect acute inflammation 
that might indicate a specific disease.[9] Since the outbreak 
of COVID-19, however, many researchers have studied changes 
in inflammatory markers in COVID-19-positive patients and 
tried to use the changes in levels of these biomarkers to 
predict disease severity and prognosis. The present study 
thus systematically reviewed all the available studies 
which investigated this relationship for better understanding 
and guide.
Methods
A literature search was conducted from May 15, 2020 for 
relevant publications published up to June 15, 2020, using 
the online databases of PubMed/Medline, Google Scholar, 
and JSTOR. The search strategy included a combination 
of “medical laboratory diagnosis, inflammatory markers, 
cytokines, acute-phase reactants, biomarkers and COVID-19, 
coronavirus, and SARS-COV-2.” Snowballing of identified 
articles was used to identify missed articles. Primary 
research articles that assessed the relationship between 
COVID-19 disease and inflammatory markers and were 
published in English were included. Studies were excluded 
if they were newsletters, expert opinions, review articles, or 
commentaries and if the research outcome was not expressed 
in median (interquartile range [IQR]) or mean (standard 
deviation [SD]). The patients were classified into severe or 
mild cases. Severe cases are patients who are either dead or 
are admitted to the intensive care units (ICU), whereas patients 
who are not in ICU were classified as mild cases. Information 
extracted from selected articles included the first author name, 
study location, study design, disease severity criteria, among 
others. The entire search protocol is presented in Figure 1.
Results
The initial search of the literature yielded a total of 548 
articles, which reduced to 412 articles after duplicates were 
removed. Following a thorough scan of the abstracts and 
titles, another set of 387 articles were further removed since 
they did not fulfill the inclusion criteria. The full texts of the 
remaining 25 articles were further evaluated after which ten 
articles were excluded either because some of the articles 
on biomarkers were not linked to COVID-19, or the full 
text was not in English and in others, the findings were not 
expressed in mean (SD) or median (IQR). Finally, 15 articles, 
which were all observational (retrospective) in design, were 
included in this systematic review [Figure 1] and comprised 
2828 COVID-19 positive patients made of 1472 (52.1%) 
males and 1356 (47.9%) females. The general characteristics 
of the included studies are presented in Table 1. The following 
inflammatory markers were identified in this study: erythrocyte 
sedimentation rate (ESR), procalcitonin (PCT), interleukin (IL) 
2, 4, 6, 8, and 10, tissue necrotic factor (TNF) gamma (ˠ) and 
alpha (α), ferritin, interferon-gamma (IF-ˠ), and serum amyloid 
A (SAA), as presented in Table 2.
Erythrocyte sedimentation rate
A total of nine studies[10-18] investigated ESR levels in the 
COVID-19-infected patients of which 8 (88.9%)[10,12,13-18] 
reported an increase in ESR among the severe cases. Three[12-14] 
of the eight cases with elevated ESR (37.5%) were statistically 
significant (P values ˂ 0.05), whereas 5 (55.6%) were not 
significant (P values ≥ 0.05). Only one study[11] reported a 
decrease in ESR among severe cases.
Procalcitonin
Eleven of the 15 articles reviewed[10,11,13-16,18-22] assessed 
PCT levels in the COVID-19 infected patients, of which 
7 (63.6%)[11,15,16,18-21] reported increase in PCT among the severe 
cases. Four[15,18,19,21] of the seven increased cases (57.1%) were 
statistically significant (P ˂  0.05), whereas 3[11,16,20] representing 
42.9% were not statistically significant (P ≥ 0.05). Only one 
study[14] reported a decrease in PCT among severe cases. Three 
of the studies (27.3%)[10,13,22] found no change in PCT level 
among the groups.
Ferritin
Changes in serum ferritin levels were investigated in four 
studies.[12,15,20,21] From the four studies, there was a 100% 
significant increase in serum ferritin in severe cases.
Tissue necrotic factor
Three studies[13,15,17] investigated TNF-α, but none of them 
shows a significant increase in TNF-α in severe cases. TNF-γ 
was reported in only one study[13] with a nonsignificant increase 
in its serum level in the severe case group.
Serum amyloid A
SAA was reported in two studies,[21,23] and the serum level 
showed an increase among the severe case group.
Interferon gamma
Zhu et al.[17] in their study investigated serum levels of IF-γ and 
reported a significant increase among the severe case group.
Interleukins
Elevated IL-6 levels were reported in eight studies with severe 
case groups[10,12-15,21,24] The increased serum level was significant 
in 75% of the studies. Three studies[13,15,17] and one study[15] that 
identified IL-10 and IL-8, respectively, reported a significant 
increase in their serum levels among the severe case groups.
IL-2 was investigated in three studies[13,15,17] and reported a 66.7% 
increase in its serum levels among the severe case groups.
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Table 1: General characteristics of the studies reviewed
Author Study design Study location Sample population Age (mean/median yearsa) Gender (%) Year of publication
10 Retrospective China 155 54 (42–66) Males: 86 (55.5)
Females: 69 (44.5)
2020





63 47 (3–85) Males: 37 (58.7)
Females: 26 (41.3)
2020
13 Retrospective China 298 57 (40–69) Males: 150 (50.3)
Females: 148 (49.7)
2020
14 Retrospective Wuhan China 69 42 (35–62) Males: 32 (46.4)
Female: 37 (53.6)
2020
15 Retrospective China 32 NA Males: 13 (40.6)
Females: 19 (59.4)
2020












299 53.4±16.7 Males: 160 (53.5)
Females: 139 (46.5)
2020
19 Retrospective China 21 56.0 (50.0–65.0) Males: 17 (81.0)
Females: 4 (19.0)
2020
20 Retrospective China 548 56 Males: 313 (57.1)
Females: 235 (42.9)
2020
21 Retrospective Zhejiang province
China
645 46.7±13.82 Males: 328 (50.9)
Females: 317 (49.1)
2020
22 Retrospective China 127 50.9 Females: 82 (64.6)
Males: 45 (35.4)
2020
23 Retrospective China 148 50 (36–64) Females: 73 (49.3)
Males: 75 (50.7)
2020
24 Retrospective Wuhan, China 19 73 (38–91) Male: 11 (57.9)
Female: 8 (42.1)
2020
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Figure 1: PRISMA flowchart of study inclusions and exclusions
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Table 2: Identified major findings in reviewed studies
Author Covid-19 
detection
Disease severity Laboratory 
parameter
Mean±SD P Disease severity 
criteriaSerum levels in mild 
cases
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8 mild cases (12.7%)
36 moderate cases 
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10 severe cases (15.9%) 
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those that recovered): 
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PCT 0.043 (0.027–0.065) 0.228 (0.119–0.991) 0.000 The Patients were 
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The critical cases: 11
The severe cases: 10 
and the mild group: 11
IL-6 2.73±1.74 Severe cases: 10.45±8.58
Critical cases: 
609.04±1501.14
0.203 All diagnosis were in line 
with the World Health 
Organization diagnostic 
criteria and the inclusion 
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National CDC of China
17 Real-time 
PCR
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the New Coronavirus 
Pneumonia Prevention 
and Control 
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diagnostic criteria was 
as set out by World 
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COVID-19
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Two studies[13,17] that reported IL-4 show that its serum levels 
increased nonsignificantly among the severe case groups.
dIscussIon
From this study, the most prevalent laboratory findings 
were increased IL-6 (100%) followed by ESR (88.9%) and 
PCT (63.6%), as seen in the previous section. In addition, 66.7% 
increase was seen in IL-2 in addition to a 100% increase in serum 
levels of ferritin, TNF-α, TNF-γ, SAA, IF-γ, IL-4, IL-8, IL-10. 
However, the number of studies where ferritin, TNF-α, TNF-γ, 
SAA, IF-γ, IL-4, IL-8, and IL-10 were reported were relatively 
small, comprising 4, 3, 1, 2, 1, 2, 1, and 3 articles, respectively, 
out of the 15 articles reviewed. About 61.2% percent (61.2%) 
and 53.1% increase in ESR and IL-6, respectively were reported 
as main findings in a similar study by Zhang et al.[3] and a 
meta-analysis of laboratory findings in COVID-19 patients also 
reported high ESR (41.8%).[25] A study comparing laboratory 
findings in COVID-19 patients with diabetes and those without 
diabetes reported increased serum levels of IL-6, ESR, SAA, 
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criteriaSerum levels in mild 
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55 (37.2%) had 
abnormal liver function
Mild cases: 93 (4.3%) 











The clinical criteria of 
diagnosis and discharge 
were as per the standards 
for “Diagnosis and 
Treatment Scheme 








SAA 65.7 (56.9–100.8) 95.1 (54.8–79.8) NA NA
NA: Not available, RT-PCR: Reverse transcription-polymerase chain reaction, SAA: Serum amyloid A, ESR: Erythrocyte sedimentation rate, 
PCT: Procalcitonin, IL: Interleukin, TNF: Tissue necrotic factor, SD: Standard deviation, CDC: Centers for disease control and prevention
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The roles of IL-6 and TNF-α in modulating immune responses 
in viral infections were reported in some studies.[26,27] According 
to these studies, viral infections are associated with elevated 
levels of TNF-α and IL-6, and the level of increase is much 
higher in the presence of bacteria co-infection.[26,27] In line with 
the above reports, we reported a 100% increase in IL-6 and 
TNF-α among the severe case groups of COVID-19 patients. 
However, the present study did not account for bacteria 
co-infection in these patients. IL-6, when secreted in excess, 
works in synergy with IL-17 to promote viral persistence 
through inhibition of cellular apoptosis and cytotoxic T-cell 
function.[28]
Changes in plasma protein types, higher chances of 
inflammation among severe group and age have been identified 
by[29] as a possible reason for increased ESR levels among the 
severe case groups of COVID-19 patients. ESR is an essential 
marker of chronic inflammatory conditions and it is known to 
increase with age.[30] Higher levels of ESR have been associated 
with poorer outcomes than their lower levels.[31]
Several studies have reported the importance of PCT in 
infections.[32-39] Although the physiological role and mechanism 
behind the changes in blood levels of PCT has not been fully 
understood, it has been reported that IF-ˠ secreted primarily 
in response to viral infections attenuate PCT[40] while in most 
bacterial infections, there is an increase blood level of PCT 
primarily due to enhanced concentrations of TNF-α, IL-1 
β, or IL-6.[35,36,41] In the present study, the 63.6% increase in 
PCT reported in individuals with severe COVID-19 infection 
could be due to bacterial co-infection in these patients. Kotula 
et al.[42] reported a significant increase in PCT levels among 
children with viral lower respiratory tract infections who were 
coinfected with a bacterial infection.
Changes in serum ferritin levels have been associated 
with liver diseases.[43,44] Hyperferritinemia has also been 
associated with viral infections.[45,46] The finding in this study 
of a 100% increase in ferritin levels in the severe cases of 
COVID-19 patients could suggest that the liver of these 
patients has been compromised. Though the lung was the 
main target organ attacked by the COVID-19 virus, a recent 
study established an association between liver injury and 
COVID-19 infection.[47] A recent meta-analysis also reported 
hyperferritinemia in patients with severe cases of COVID 19.[29]
Elevated levels of inflammation-related biomarkers seen in this 
study are a pointer that organ injuries are much more serious 
in this group of patients. The rapid deterioration of patients 
with COVID-19 could eventually be the outcome due to the 
susceptibility of these patients to form an inflammatory storm.[8]
The main limitation of this study is the fact that all the studies 
were from China; however, in the absence of data from 
other countries, the findings from this study can still suffice. 
Although it is a challenge for other countries to take a cue 
from this type of research and practice, especially during this 
COVID-19 pandemic.
conclusIon
COVID-19 patients are susceptible to the inflammatory storm, 
and the severity of the infection correlates positively with 
inflammatory markers, especially IL-6, ESR, and PCT. The 
relationship between other biomarkers such as serum ferritin, 
TNF-α, TNF-γ, SAA, IF-γ, IL-4, IL-8, IL-10 requires further 
studies. It is, therefore, recommended that serum levels of these 
biomarkers should be closely monitored as a guide to assess 
the severity of COVID-19 patients. Randomized clinical trials 
and large population studies are still required to evaluate the 
observations in this study and also explain the mechanism of 
these inflammatory markers with the severity of COVID-19.
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